Bristol-Myers Squibb International — Property, plant and equipment increased by 44.6% to $2.32B in Q4 2024 compared to the prior quarter.
An increase suggests expansion of international manufacturing or research infrastructure, while a decrease may indicate asset divestiture, impairment, or a shift toward third-party contract manufacturing.
This metric represents the net book value of tangible long-term assets, such as manufacturing facilities, laboratories,...
Peer pharmaceutical companies typically report this as part of their regional segment disclosures, with levels varying based on whether the firm utilizes internal manufacturing or outsourced production models.
bmy_segment_international_property_plant_and_equipment| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | |
|---|---|---|---|---|
| Value | $1.34B | $1.42B | $1.61B | $2.32B |
| QoQ Change | — | +6.2% | +12.9% | +44.6% |
| YoY Change | — | +6.2% | +12.9% | +44.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.